MetaCap

Alector Inc. (ALEC)

NASDAQ: ALECHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.34+0.035 (+1.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ALEC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$347.63M
52-week range
1.09 – 2.84
Day range
2.28 – 2.47
Volume / Avg
1.95M / 3.34M
Beta
—

52-week range

$1.09$2.84

ALEC stock today

On Nov 20, ALEC ended the session at $2.34, adding $0.035 (1.52%), versus the S&P 500's 3.70% decline. Shares are 17.8% below their 52-week high of $2.84, set on Nov 11, 2026 and 114.2% above the 52-week low of $1.09, in the middle of the past year's range. ALEC is up 49.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 88.3%.

Alector trades at 6.3x its trailing twelve-month earnings per share of $0.37.

Summary generated from market data by MetaCap's automated system. Methodology

About Alector

Company profile

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Arnon Rosenthal Ph.D.
Headquarters
South San Francisco, CA
Employees
103
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Alector generated $21.0 million in revenue, down 79.1% from fiscal 2024, its first annual decline since 2023. Alector reported a net loss of $142.9 million, compared with a loss of $119.0 million a year earlier. Operating margin was -741.3%.

Alector annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$21.05M$100.56M$97.10M$133.60M$207.09M
Growth-79.07%+3.56%-27.32%-35.49%+881.54%
Net income$-142.93M$-119.05M$-130.39M$-133.31M$-36.33M
EPS (diluted)$-1.39$-1.23$-1.56$-1.62$-0.45

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$4.42+89.29%

  • Strong buy 0
  • Buy 4
  • Hold 2
  • Sell 1
  • Strong sell 1

Target range

Low $1.00High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$1.11 vs $-0.23
Surprise
+582.61%

ALEC news

All ALEC news

Alector peers

Health Care sector
ALEC peer companies
CompanyPrice% ChgMarket capCompare
CCCCC4 Therapeutics Inc.2.48+1.64%$325.67Mvs ALEC
SLBTSL Science Holding Limited0.55-3.36%$308.42Mvs ALEC
XFORX4 Pharmaceuticals Inc.3.00+1.35%$306.34Mvs ALEC
TRXBTRex Bio Inc.10.32+6.12%$296.95Mvs ALEC
CADLCandel Therapeutics Inc.5.04-1.75%$395.37Mvs ALEC
DTILPrecision BioSciences Inc.7.40+7.09%$282.46Mvs ALEC
TVGNTevogen Inc.5.90-6.35%$405.20Mvs ALEC
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs ALEC

Indexes, lists and sector

Alector stock FAQ

What is Alector's stock price today?

ALEC last traded at $2.34 as of Nov 20, 4:00 PM EST, up 1.52% on the day. Prices are delayed at least 15 minutes.

What is ALEC's P/E ratio?

ALEC trades at a trailing P/E ratio of 6.31.

Who is Alector's CEO?

Dr. Arnon Rosenthal Ph.D. is the chief executive officer of Alector Inc., which has about 103 employees.

What is the ALEC 52-week high?

The 52-week high for ALEC is $2.84 and the 52-week low is $1.09. The stock is currently 17.8% below its high.

Compare ALEC